Financial News · Live Terminal

Page 342 of 417

Research104d ago

Morgan Stanley Downgrades China State Construction Engineering to Underweight from Overweight; Price Target is 4.70 Yuan

SHA:601668

Research104d ago

Morgan Stanley Downgrades Anhui Conch Cement Company to Equalweight from Overweight; Price Target is HK$21.70

HKG:0914SHA:600585

Research104d ago

Capital Securities Upgrades Winbond Electronics to Buy from Neutral; Price Target is NT$116

TPE:2344

Research104d ago

Capital Securities Downgrades Yang Ming Marine Transport to Neutral from Buy; Price Target is NT$52

TPE:2609

Research104d ago

Compass Point Initiates Invitation Homes at Neutral With $30 Price Target

Invitation Homes (INVH) has an average rating of overweight and mean price target of $30.52, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$INVH

Research104d ago

Morgan Stanley Upgrades Garmin to Equalweight From Underweight, Adjusts PT to $252 From $195

Garmin (GRMN) has an average rating of hold and mean price target of $261.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$GRMN

Research104d ago

Morgan Stanley Upgrades Phillips 66 to Overweight From Equalweight, Adjusts PT to $174 From $147

Phillips 66 (PSX) has an average rating of overweight and mean price target of $182.72, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$PSX

Research104d ago

Morgan Stanley Downgrades CSX to Underweight From Equalweight, Price Target is $30

CSX (CSX) has an average rating of overweight and mean price target of $45.84, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CSX

Research104d ago

Baird Upgrades Old Dominion Freight Line to Neutral From Underperform, Adjusts PT to $229 From $204

Old Dominion Freight Line (ODFL) has an average rating of hold and mean price target of $207.77, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$ODFL

Research104d ago

UBS Downgrades Nucor to Neutral From Buy, Adjusts Price Target to $224 From $190

Nucor (NUE) has an average rating of overweight and mean price target of $207.42, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$NUE

Research104d ago

Research Alert: Ccep Meets Q1 Estimates On Calendar Boost; Underlying Demand Growth Modest

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CCEP reported Q1 2026 revenue of EUR5.00B, in line with consensus of EUR4.99B. FXN revenue growth of 9.4% was led by strong reported volume growth of 8.5%, though comparable volume growth of 1.6% after adjusting for six additional consumption days provides a more accurate demand picture. Revenue per unit case growth was moderate at 0.8%, with Europe posting 1.3% expansion while APS declined 0.3% due to the Suntory alcohol exit impact. The energy category delivered exceptional 21.3% volume growth from Monster brand distribution gains. However, we do not expect sustainable outperformance given potential consumer choice overload from excessive innovation. Management reaffirmed 2026 targets of 3-4% FXN revenue growth and ~7% comparable operating profit growth, which compare well with consensus estimates. However, we maintain a grounded view given the challenging consumer environment with an ongoing focus on value and affordability, which limits price growth potential and necessitates sustained promotions.

$CCEP

Research104d ago

Research Alert: Bp: Q1 2026 Exceptional Performance May Not Be Sustainable

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BP's Q1 2026 RC profit of USD3.2B (+2.1x Y/Y) was within market expectations but exceeded ours, representing 25% of 2026's consensus estimates and 47% of ours. This dramatic reversal from Q4's 30% sequential decline was boosted by strong oil trading and higher realized refining margins of USD16.9/bbl versus Q4's USD15.2/bbl. We have sustainability concerns about this windfall performance, particularly the customers & products' exceptional 2.1x sequential surge. Management warned of multiple Q2 2026 headwinds, including lower upstream production from seasonal maintenance and Middle East disruptions, lower midstream results, and higher refinery turnaround activity. Updated 2026 guidance now expects reported upstream production to be lower rather than broadly flat as previously guided, with underlying production guidance remaining broadly flat versus previous growth expectations, suggesting Middle East disruptions are having more severe operational impacts than initially anticipated.

$BP

Research104d ago

Research Alert: Barclays Delivers In-line Q1 With Broad-based Growth; Reaffirms All Targets

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Barclays delivered solid Q1 2026 results with profit before tax of GBP2.81B (+3% Y/Y) and RoTE of 13.5%, in line with consensus expectations of GBP2.83B. Total income grew 6% to GBP8.16B, reflecting broad-based performance, with the Investment Bank achieving record quarterly income exceeding GBP4B (Global Markets up 6%, Banking fees up 17%) and U.K. businesses continuing growth with net interest income (NII) up 12%. We believe Barclays remains on track to achieve its targets given the momentum shown in Q1 2026, with all divisions achieving double-digit returns, including the U.S. Consumer Bank RoTE improving to 18.8% from 4.5%. Management reaffirmed all 2026 and 2028 financial targets, expressing confidence in achieving more than 12% RoTE in 2026 and more than 14% in 2028, supported by its diversified platform. Capital strength remains robust with a 14.1% CET1 ratio near the top of its 13%-14% target range, supporting the announced GBP500M share buyback following completion of the ongoing GBP1.0B program.

$BCS

Research104d ago

Research Alert: Novartis Q1 2026 Results Miss On U.s. Generic Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Novartis' Q1 2026 results came in below consensus, with net sales declining 1% (-5% in constant currencies [cc]) and core EPS of USD1.99 missing the consensus of USD2.08. Core operating income fell 14% cc, with margin contracting 4.1%-pts to 37.3% as generic pressures intensified, particularly for Entresto, which declined 46% cc. Growth products Kisqali (+55% cc) and Pluvicto (+70% cc) provided some offset to the generic headwinds. Novartis reiterated its 2026 guidance for low-single-digit sales growth cc and a low-single-digit core operating income decline cc, expecting a challenging 1H before a 2H improvement. Multiple Phase 3 readouts expected in 2H 2026, including remibrutinib in multiple sclerosis, could strengthen the mid- to long-term growth outlook. In our view, while the company has solid growth momentum in newer assets and a broad pipeline, Entresto represents the single largest near-term patent risk among European peers, limiting the potential for rapid replacement despite growth in other products.

$NVS

Research104d ago

Research Alert: CFRA Keeps Hold Opinion On Shares Of Principal Financial Group

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $12 to $108, valuing PFG shares at 11.8x our 2026 operating EPS estimate of $9.12 (raised by $0.02) and at 10.7x our 2027 EPS estimate of $10.10 (upped by $0.18). This compares to the shares' one-year average forward multiple of 9.5x and a peer average of 8.3x. We lower our operating revenue forecast for 2026 to flat to 3% growth (versus our previous forecast of a 3% to 6% rise in revenues), but we keep our 2027 revenue forecast of a 3% to 6% rise. Q1 2026 operating revenues sank by 13% on 34% lower premiums, partly offset by 3.7% higher fee income and a 2.9% rise in net investment income. Weighing the broad based margin improvement in Q1 with a declining revenue base and the shares' premium valuation to peers ad historical averages, we view the shares as fairly valued.

$PFG

Research104d ago

Nomura Downgrades Sungrow Power Supply to Neutral from Buy, Adjusts Price Target to 120 Yuan from 230 Yuan

SHE:300274

Research105d ago

Research Alert: CFRA Maintains Buy View On Shares Of Honeywell International Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target to $250 from $260 following a mixed Q1 print, valuing shares at 21.5x our 2027 EPS outlook of $11.65 (lowered from $11.75; 2026 EPS estimate raised by $0.02 to $10.60). HON delivered mixed top-line results in Q1 2026, with overall organic sales growing 2% as strong 8% growth in Building Automation was offset by headwinds elsewhere. Specifically, Aerospace growth was held to just 3% by temporary supply chain constraints, while Process Automation & Technology sales declined 6% due to project timing. In contrast to modest sales growth, profitability was broadly positive, with segment margin expanding 90 bps to 23.3%, supported by strong pricing, productivity gains, and removal of stranded costs. Regarding its portfolio transformation, the company announced it is tracking ahead of schedule, setting a completion date of June 29, 2026, for the upcoming Aerospace spin-off and confirming that financing and leadership teams for both companies are in place.

$HON

Research105d ago

Research Alert: Qiagen Cuts 2026 Outlook As Q1 Sales Miss On Weak Quantiferon Testing

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Qiagen's preliminary Q1 2026 net sales fell by 1% CER, missing the company's outlook for at least 1% growth, while reported sales grew 2% to USD492M, below consensus' USD501M. Preliminary adjusted EPS of USD0.54 was in line with the outlook, though overall results were dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. The company downgraded 2026 guidance to 1%-2% CER sales growth (from at least 5% previously) and adjusted EPS to at least USD2.43 CER (from USD2.50 previously), expecting stronger trends in 2H, supported by acquisition benefits and sequential QuantiFERON improvement. We view the sales miss and lowered outlook as disappointing, but still see QuantiFERON as a main growth contributor, while the Parse acquisition should strengthen Qiagen's competitive position. That said, monitoring progress in other patient testing groups for QuantiFERON remains key. Full Q1 results are scheduled for May 6, 2026.

$QGEN

Research105d ago

Research Alert: Shell Agrees To Buy Arc Resources For Usd16.4b

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Shell announced the acquisition of ARC Resources for USD16.4B enterprise value, offering CAD32.80 per share (20% premium to 30-day VWAP) through 25% cash and 75% equity consideration, expected to close in 2H 2026. The transaction will immediately add 370 kboe/d production, representing a substantial 20% increase to Shell's current 1.8M boe/d output. We believe the deal establishes Canada as a core operating region and accelerates Shell's production CAGR from 1% to 4% through 2030. Management expects USD250M in annual synergies while maintaining USD20B-USD22B capex guidance and 40%-50% cash flow distribution policy. However, Shell is paying USD44k per boe/d at the higher range of recent Canadian E&P multiples, with 75% equity consideration diluting existing shareholders by 3% and delaying free cash flow accretion until 2027. In our view, value creation will depend on Shell achieving operational improvements materially beyond stated synergies while maintaining capital efficiency metrics.

$SHEL

Research105d ago

Research Alert: Nucor Posts Strong Q1, Beats On Revenue And Eps

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Nucor reported Q1 2026 adjusted EPS of $3.23, significantly above $0.77 prior year and beating consensus by $0.41, with revenues of $9.50B exceeding estimates by 7.1%. Steel mills posted record quarterly shipments of 7.0M tons with segment earnings more than doubling sequentially to $1.128B as external pricing improved to $1,074 per ton (+14% Y/Y) and utilization climbed to 86%. We believe operational execution remains strong across segments, with steel products earnings rising 24% sequentially and broad-based volume recovery evident. Management guided for higher Q2 earnings across all segments on price improvement and stable to growing volumes. With capex declining 18% sequentially to $661M and $2.48B in cash, Nucor returned $250M to shareholders with $3.97B remaining under buyback authorization. We expect accelerating free cash flow generation will support enhanced shareholder returns, though valuation ultimately depends on pricing power persistence amid upcoming industry capacity additions in 2027.

$NUE

Showing 6821-6840 of 8331